Evidence map›Paper›PMID 20194829›Full record

Trial reportArchives of general psychiatry2010

A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Carlos Blanco, Richard G Heimberg, Franklin R Schneier, David M Fresco, Henian Chen, Cynthia L Turk, Donna Vermes, Brigette A Erwin, Andrew B Schmidt, Harlan R Juster and 2 more

Open access · greenAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Archives of general psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 6 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 6 syntheses or guidelines pooled it, 206 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacotherapy for social anxiety disorder (SAnD).The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Anxiety and depression in emerging adults: The STAND program as a model of scalable screening and intervention.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Carlos BlancoDepartment of Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons of Columbia University,1051 Riverside Dr, Box 69, New York, NY 10032, USA. cb255@columbia.edu
Richard G Heimberg
Franklin R Schneier
David M Fresco
Henian Chen
Cynthia L Turk
Donna Vermes
Brigette A Erwin
Andrew B Schmidt
Harlan R Juster
Raphael Campeas
Michael R Liebowitz
Columbia University · US

Funding

UVAR PHOTOPHERESIS SYSTEM IN CONJUNCTION WITH UVADEXM01RR000349 · NCRR · TEMPLE UNIVERSITY · PI BODEN, GUENTHER · 1985 to 2002
$4.2M
PHARMACOTHERAPY OF SOCIAL PHOBIAR01MH044119 · NIMH · TEMPLE UNIVERSITY · PI HEIMBERG, RICHARD G · 1988 to 2001
$632k
Bridging Efficacy and Effectiveness in Drug Abuse TreatmentK02DA023200 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BLANCO, CARLOS · 2008 to 2012
$618k
LONG-TERM TREATMENT OF SOCIAL PHOBIAR10MH057148 · NIMH · TEMPLE UNIVERSITY · PI HEIMBERG, RICHARD G · 1996 to 2000
$101k
PHARMACOTHERAPY OF SOCIAL PHOBIAR10MH044119 · NIMH · TEMPLE UNIVERSITY · PI HEIMBERG, RICHARD G · 1995 to 1999
–
NCRR NIH HHS M01 RR000349NCRR NIH HHS RR00349NIDA NIH HHS DA023200NIDA NIH HHS K02 DA023200NIMH NIH HHS MH44119NIMH NIH HHS MH57148NIMH NIH HHS R01 MH044119NIMH NIH HHS R10 MH057148
6 · The paper itself

Abstract

contextMedication and cognitive behavioral treatment are the best-established treatments for social anxiety disorder, yet many individuals remain symptomatic after treatment.

objectiveTo determine whether combined medication and cognitive behavioral treatment is superior to either monotherapy or pill placebo.

designRandomized, double-blind, placebo-controlled trial.

settingResearch clinics at Columbia University and Temple University.

participantsOne hundred twenty-eight individuals with a primary DSM-IV diagnosis of social anxiety disorder.

interventionsCognitive behavioral group therapy (CBGT), phenelzine sulfate, pill placebo, and combined CBGT plus phenelzine.

main outcome measuresLiebowitz Social Anxiety Scale and Clinical Global Impression (CGI) scale scores at weeks 12 and 24.

resultsLinear mixed-effects models showed a specific order of effects, with steepest reductions in Liebowitz Social Anxiety Scale scores for the combined group, followed by the monotherapies, and the least reduction in the placebo group (Williams test = 4.97, P < .01). The CGI response rates in the intention-to-treat sample at week 12 were 9 of 27 (33.3%) (placebo), 16 of 34 (47.1%) (CBGT), 19 of 35 (54.3%) (phenelzine), and 23 of 32 (71.9%) (combined treatment) (chi(2)(1) = 8.76, P < .01). Corresponding remission rates (CGI = 1) were 2 of 27 (7.4%), 3 of 34 (8.8%), 8 of 35 (22.9%), and 15 of 32 (46.9%) (chi(2)(1) = 15.92, P < .01). At week 24, response rates were 9 of 27 (33.3%), 18 of 34 (52.9%), 17 of 35 (48.6%), and 25 of 32 (78.1%) (chi(2)(1) = 12.02, P = .001). Remission rates were 4 of 27 (14.8%), 8 of 34 (23.5%), 9 of 35 (25.7%), and 17 of 32 (53.1%) (chi(2)(1) = 10.72, P = .001).

conclusionCombined phenelzine and CBGT treatment is superior to either treatment alone and to placebo on dimensional measures and on rates of response and remission.

Indexed as

AdolescentAdultAgedCognitive Behavioral TherapyCombined Modality TherapyDiagnostic and Statistical Manual of Mental DisordersFemaleHumansMaleMiddle AgedMonoamine Oxidase InhibitorsPhenelzinePhobic DisordersPlacebosPsychiatric Status Rating ScalesPsychometricsMonoamine Oxidase InhibitorsPhenelzinePlacebos

Identifiers

PMID20194829
PMCPMC2856667
OpenAlexW1990056753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.